Cargando…
Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer
The five-year survival rate for metastatic pancreatic cancer is currently only 3%, which increases to 13% with local invasion only and to 39% with localized disease at diagnosis. Here we evaluated repurposed mebendazole, an approved anthelminthic drug, to determine how mebendazole might work at the...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274724/ https://www.ncbi.nlm.nih.gov/pubmed/34262644 http://dx.doi.org/10.18632/oncotarget.28014 |